Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 16,678

Document Document Title
WO/2018/071640A1
The invention relates to a peptide of formula (I) R1-Wm-Xn-AA1-AA2-AA3-Yp-Zq-R2, cosmetic or pharmaceutical compositions comprising same and its use, for example, in the reduction of lipid accumulation in the skin, the treatment of cellu...  
WO/2018/070829A1
The present invention relates to an expression cassette for preparing a copper peptide and use thereof, and more specifically, to an expression cassette for preparing a copper peptide comprising a polynucleotide sequence encoding a pepti...  
WO/2018/071556A1
Provided are methods of identifying, visualizing and purifying proteases from a complex biological sample.  
WO/2018/071761A1
A mitochondrial-targeted PARP inhibitor is provided herein, as well as methods of making and using the mitochondrial-targeted PARP inhibitor.  
WO/2018/066545A1
Provided is a drug that can decompose a target intracellular protein specifically and is effective for the prevention or treatment of diseases associated with the target protein. An SNIPER compound produced by linking a specific IAP liga...  
WO/2018/066914A1
The present invention relates to a tripeptide having fatty acids bonded thereto and a cosmetic composition comprising same and provides excellent skin anti-aging, wrinkle reduction, skin elasticity enhancement, and skin permeation effects.  
WO/2018/067457A1
An apparatus and method for performing analysis and identification of molecules have been presented. In one embodiment, a portable molecule analyzer includes a sample input/output connection to receive a sample, a nanopore-based sequenci...  
WO/2018/052949A1
The present disclosure provides compounds represented by Formula I: I, and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3, R4, Ar, L, X, Y, and B are as defined as set forth in the specifi...  
WO/2018/053109A1
This invention provides a process tor characterizing a glatiramer acetate related drug substance - or drug product comprising the steps of: (a) obtaining a batch of the glatiramer acetate related drag substance or drug product; (b) conta...  
WO/2018/053049A1
Provided herein are polynucleic acids and expression vectors for the expression and secretion of angiotensin peptide fragments (e.g., angiotensin-(1-7)) in probiotic bacteria. Provided herein are also probiotic compositions that enable e...  
WO/2018/053135A1
The present disclosure provides a novel sweetener composition of improved taste of the sweetener (e.g., reduced bitterness and/or astringency, and improved overall sweet quality of the composition); food and beverage products containing ...  
WO/2018/050663A1
The present invention relates to novel compounds which effectively inhibit the melanin synthesis in human melanocytes and are thus suitable for the treatment of senile lentigines, for smoothening skin color irregularities and/or for ligh...  
WO/2018/044012A1
The present invention relates to a peptide having anticancer activity, and a cancer preventing and treating pharmaceutical composition, functional health food composition and functional cosmetic composition containing same as an active i...  
WO/2018/036942A1
The invention provides novel compounds having the general formula (I): (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, A, X and R11 are as described herein, compositions including the compounds and methods of using the compounds.  
WO/2018/035610A1
The present invention provides 18F-labeled amino acids or derivatives thereof having formula (I) and methods of making same, which can be suitable for PET imaging: (Formula (I)).  
WO/2018/035519A1
The present invention relates to compositions and methods for the treatment or prevention of autoimmune diseases such as demyelination disorders. The invention includes a composition comprising a peptide antigen comprising at least one b...  
WO/2018/034356A1
The present invention provides a peptide comprising an amino acid sequence represented by any of formulas (I)-(III), and a conjugate comprising the peptide and a functional part. (I) The amino acid sequence (X1) [D]P[D](X2)[D] (in the se...  
WO/2018/034901A1
Disclosed are methods of making elamipretide (MTP-131), a peptide compound with therapeutic potential for treating various mitochondrial myopathies. The synthesis of the peptide can be achieved via the use of N-carboxyanhydride-modified ...  
WO/2018/031690A1
Compounds and compositions are disclosed in which a Drug Unit is linked to a targeting Ligand Unit through a self-stabilizing Linker Unit from which a drug compound or active drug moiety is released at the targeted site of action. Method...  
WO/2018/028634A1
Salts of compound (I) and pharmaceutically compositions thereof, specially a base addition salt, an acid addition salt of compound (I) and a pharmaceutically composition thereof, future the use of the compound and the pharmaceutical comp...  
WO/2018/024645A1
The present invention relates to a process for preparation of Carfilzomib of formula (I).  
WO/2018/018863A1
Disclosed are a mild and efficient preparation method for an α-acyloxy alkenyl amide compound and a use thereof in the synthesis of an amide and a polypeptide. The α-acyloxy alkenyl amide compound is obtained by an addition reaction of...  
WO/2018/022937A1
The present invention provides novel peptide inhibitors of interleukin-23, and related methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, Crohn's disea...  
WO/2018/019196A1
A substituted boric acid compound, a pharmaceutical composition comprising same, and an application thereof. The substituted boric acid compound is a compound represented by formula (I), or a crystal form, a pharmaceutically acceptable s...  
WO/2018/022866A1
The present invention provides a compound of formula (I) or a salt thereof and their use as a biomarker in assessing or monitoring kidney function in a subject, determining predisposition to developing reduced kidney function, classifyin...  
WO/2018/023028A1
Disclosed is a rapid, non-invasive and highly specific and sensitive diagnostic assay for the identification of individuals with synucleinopathy and for measuring synucleinopathy progression or status. Test kits for diagnosis of an indiv...  
WO/2018/012901A1
The present invention relates to a pharmaceutical composition for cell protection containing cyclo histidine-proline (cyclo His-Pro, CHP) as an active ingredient. The pharmaceutical composition for cell protection containing cyclo histid...  
WO/2018/006667A1
Disclosed are antihypertensive peptides and antihypertensive proteins and a use thereof. The amino acid sequences of the antihypertensive peptides are respectively TTW, VHW and KAKW, and the amino acid sequences of the antihypertensive p...  
WO/2018/007495A1
The present invention relates to compounds of formula (I) and compositions comprising them for use in enhancing umami taste and/ or saltiness of a food product.  
WO/2018/007496A1
The present invention relates to compounds and compositions for use in enhancing flavor and/or saltiness of a food product. Particularly, the present invention relates to compounds of the general formula I) and compositions comprising them.  
WO/2018/008902A1
The present invention relates to a psoriasis-induced animal model and a use thereof and, more particularly, to: a psoriasis-induced animal model transformed such that a Pellino homolog 1 (Peli1) gene is overexpressed according to the adm...  
WO/2018/000079A1
Novel cyclic peptide GHRP-6 analogs of formula (I): (I) or pharmaceutically acceptable esters or salts thereof, are described. These cyclic peptide GHRP-6 analogs may be used for modulating CD36 activity, for example for the treatment of...  
WO/2018/001332A1
A compound having an inhibitory activity against a mutant isocitrate dehydrogenase, a preparation method therefor and use thereof, particularly a compound represented by formula I, or a pharmaceutically acceptable salt thereof, or an ena...  
WO/2018/004281A2
Disclosed are a tranexamic acid-peptide having a skin whitening effect and skin whitening activity with excellent thermal stability and time stability, which is capable of inducing return to healthy skin and whitening effect through skin...  
WO/2018/004281A3
Disclosed are a tranexamic acid-peptide having a skin whitening effect and skin whitening activity with excellent thermal stability and time stability, which is capable of inducing return to healthy skin and whitening effect through skin...  
WO/2018/001273A1
Provided are a peptide or a salt thereof, and a preparation method therefor. The peptide may be selected from VVYP, AVLP, IGFP, LLIIVP and STAP. The preparation method comprises steps as follows: using a resin as a starting material, lin...  
WO/2018/005332A1
Endomorphin-2 and tetrapeptide derivatives thereof are described. Pharmaceutical or cosmetic compositions containing endomorphin-2 or a tetrapeptide derivative thereof are therapeutically effective to treat, improve or prevent pain in hu...  
WO/2017/223098A1
Compositions comprising bis(tryptophan) derivatives are provided that act as antimicrobials. Also provided are methods for reversing antibiotic resistance in a bacterium, or recovering or enhancing antimicrobial activity of an antibiotic...  
WO/2017/219808A1
Provided are a compound as shown in formula (I) usable as a hepatitis C virus inhibitor, or an optical isomer, a pharmaceutically acceptable salt, a hydrate or a solvate thereof, usable to treat hepatitis C virus (HCV) infections or hepa...  
WO/2017/217535A1
Provided is a novel peptide having an ACE inhibitory activity. More particularly, provided is a tripeptide comprising Leu-Arg-Ala.  
WO/2017/217728A1
The present invention relates to: a composition for promoting angiogenesis, a pharmaceutical composition for preventing or treating angiogenesis-dependent diseases, and a quasi-drug and cosmetic composition for skin regeneration, all of ...  
WO/2017/217855A1
Disclosed are geminoid peptide-like compound according to Formula (I): R1 - C(=0) - Zn - NR3 - R2 in which R1 and R2 are each independently saturated, partly saturated or unsaturated, straight, branched or cyclic alkyl chains, wherein R1...  
WO/2017/216177A1
The peptide has from 3 to 10 amino acids comprising at least the sequence K*(Ac)GH or K*(Ac)HG and may further comprise an N-terminus modification, preferably an acylation, and/or a C-terminus modification; K* is selected from the group ...  
WO/2017/211818A1
The present invention relates to a compound of formula (I), wherein X is C=0, C=S or B-OH; Y is an electrophile and Z is a leaving group, or Y══Z is an electrophile; R1 comprises or consists of (a) (i) a first group binding to a prot...  
WO/2017/214534A1
The invention provides a copper-mediated process for making compounds according to Formula (I): that are the macrocyclic scaffolds of the arylomycin class of biologically active compounds, where R1, R2, R3, RA1, RA2, RA3, B, G1, G2, PG, ...  
WO/2017/214076A1
The present invention describes rhomboid protease inhibitors having high specificity and inhibition characteristics providing novel antibiotics, anti-malarial pharmaceutical agents, and provides a strategy for designing RiBns (rhomboid-i...  
WO/2017/211272A1
The present invention provides a phenyl propanamide derivative as represented by formula (I), a manufacturing method of the derivative, application of the derivative as a κ-opioid receptor (KOR) agonist, and application of the derivativ...  
WO/2017/207546A1
The present invention relates to washing or cleaning compositions, preferably liquid washing compositions, comprising at least one protease, at least one compound of the formula (I) and/or of the formula (II) that acts as a protease inhi...  
WO/2017/209805A1
A variety of hydrophobically modified polypeptoids are provided. The hydrophobically modified polypeptoids can include a polyamide backbone having a random copolymer of two or more different types of repeat units, where one or more of th...  
WO/2017/205392A1
The present invention provides polymeric pegylated carfilzomib compounds, and pharmaceutically acceptable salts thereof, of Formula I wherein R1, R2, linker, PEG, n and o are as defined herein. The invention also provides methods of maki...  

Matches 1 - 50 out of 16,678